{{noteTA
|1=zh-cn:伊立替康; zh-tw:愛萊諾迪肯;
|2=zh-cn:开普拓; zh-tw:抗癌妥;
|3=zh-cn:结直肠癌; zh-tw:大腸癌;
}}
{{medical}}
{{Drugbox|
|IUPAC_name = (''S'')-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-<br />3,14-dioxo1''H''-pyrano[3’,4’:6,7]-indolizino[1,2-b]quinolin-<br />9-yl-[1,4’bipiperidine]-1’-carboxylate
| image = irinotecan.svg
| width = 240px
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number=100286-90-6
| ATC_prefix=L01
| ATC_suffix=XX19
| PubChem=3750
| DrugBank=APRD00579
| IUPHAR_ligand = 6823
| CAS_number2_Ref = {{cascite|changed|CAS}}
| CAS_number2 =  97682-44-5
| PubChem2 = 60838
| DrugBank2_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank2 = DB00762
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 80630
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54825
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7673326042
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08086
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 481
| C = 33 |H = 38 |N = 4 |O = 6
| molecular_weight = 586.678 [[克|g]]/[[莫耳|莫耳]]<br />677.185 g/mol ([[hydrochloride|hydrochloride]])
| bioavailability= NA
| metabolism = [[Liver|Hepatic]] [[glucuronidation|glucuronidation]]
| elimination_half-life= 6 to 12 [[hour|hour]]s
| excretion =  Biliary and [[Kidney|renal]]
| pregnancy_category = D <small>([[Australia|Au]], [[United_States|U.S.]])</small>
| legal_status = [[Prescription_drug|POM]] <small>([[United_Kingdom|UK]])</small>, ℞-only <small>(U.S.)</small>
| routes_of_administration= [[靜脈注射|靜脈注射]]
}}
{{各地中文名|cn=伊立替康|tw=愛萊諾迪肯}}
'''愛萊諾迪肯'''（{{lang|en|Irinotecan}}），商品名'''抗癌妥'''（{{lang|en|Campto}}），是一種[[拓撲異構酶|拓撲異構酶]]I抑制物，主要用來治療[[大腸癌|大腸癌]]及[[小細胞癌|小細胞癌]]，也可以在最初的療程失敗後，與[[5-氟尿嘧啶|5-氟尿嘧啶]]及亞葉酸治療[[胰腺癌|胰腺癌]]<ref>{{cite web|title=Onivyde (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf|website=FDA|accessdate=13 February 2018|date=2015|archive-date=2019-10-13|archive-url=https://web.archive.org/web/20191013125335/https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf|dead-url=no}}</ref>。通常會與其他化學治療藥物一起使用，並且以[[靜脈注射|靜脈注射]]的方式。常見的副作用包括[[腹瀉|腹瀉]]、[[嘔吐|嘔吐]]、脫髮和[[發燒|發燒]]等。

==參考資料==
{{reflist}}

==外部連結==
* [http://camptosar.com/products/camptosar.aspx Pfizer website] {{Wayback|url=http://camptosar.com/products/camptosar.aspx |date=20070929033031 }}
* [http://www.pharmgkb.org/do/serve?objId=PA2001&objCls=Pathway Irinotecan Pathway on PharmGKB] {{Wayback|url=http://www.pharmgkb.org/do/serve?objId=PA2001&objCls=Pathway |date=20070827102153 }}

{{化疗药物}}

[[Category:前药|Category:前药]]
[[Category:輝瑞產品|Category:輝瑞產品]]
[[Category:拓扑异构酶抑制剂|Category:拓扑异构酶抑制剂]]
[[Category:哌啶|Category:哌啶]]
[[Category:内酰胺|Category:内酰胺]]
[[Category:Δ-内酯|Category:Δ-内酯]]
[[Category:吡喃吲嗪喹啉|Category:吡喃吲嗪喹啉]]